Quantum Biopharma Ltd. (QNTM)

Quantum Biopharma Ltd. is a biopharmaceutical company based in Toronto, Canada, whose Class B subordinate voting shares trade on the Nasdaq Stock Market under the ticker QNTM. The company was formerly known as FSD Pharma.

Its lead drug candidate, Lucid-MS, is a novel compound being developed for multiple sclerosis with the aim of preventing and reversing myelin degradation, the process that damages nerve fibers in the disease. The company has advanced Lucid-MS through early-stage clinical work.

Quantum Biopharma has also been involved in developing products aimed at alcohol misuse, including the unbuzzd formulation, and retains interests connected to that business.